FDA approves at least one more rare disease drug by 2026-11-30

Makary's tenure saw controversies over rejecting rare disease drugs, but his successor may prioritize faster approvals to address these treatments. Given Trump's focus on deregulation, a shift toward approving more rare disease drugs is likely.

Implied probability (Yes)

70%